{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T21:30:25Z","timestamp":1781818225333,"version":"3.54.5"},"reference-count":95,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100010014","name":"Six Talent Peaks Project in Jiangsu Province","doi-asserted-by":"publisher","award":["2016-SWYY-CXTD-008"],"award-info":[{"award-number":["2016-SWYY-CXTD-008"]}],"id":[{"id":"10.13039\/501100010014","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["DA032837"],"award-info":[{"award-number":["DA032837"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["DA040693"],"award-info":[{"award-number":["DA040693"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brain Research"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.brainres.2018.08.025","type":"journal-article","created":{"date-parts":[[2018,8,24]],"date-time":"2018-08-24T03:00:30Z","timestamp":1535079630000},"page":"145922","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"special_numbering":"C","title":["Therapeutics development for addiction: Orexin-1 receptor antagonists"],"prefix":"10.1016","volume":"1731","author":[{"given":"David A.","family":"Perrey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7153-4358","authenticated-orcid":false,"given":"Yanan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.brainres.2018.08.025_b0005","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3389\/fnins.2014.00107","article-title":"Pharmacological or genetic orexin1 receptor inhibition attenuates MK-801 induced glutamate release in mouse cortex","volume":"8","author":"Aluisio","year":"2014","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.brainres.2018.08.025_b0010","unstructured":"Alvaro, G., Amantini, D., Castiglioni, E., Di Fibio, R., Pavone, F., 2010. (WO2010063663) N-{[(IR,4S,6R-3-(2-pyridinylcarbonyl)-3-azabicyclo [4.1.0]hept-4-YL] methyl}-2-heteroarylamine derivatives and uses thereof. WO 2010\/063663."},{"key":"10.1016\/j.brainres.2018.08.025_b0015","unstructured":"Alvaro, G., Amantini, D., Stasi, L.P., 2009. Pyridine derivatives used to treat orexin related disorders. WO 2009124956."},{"key":"10.1016\/j.brainres.2018.08.025_b0020","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3389\/fnins.2014.00033","article-title":"Orexin-1 and orexin-2 receptor antagonists reduce ethanol self-administration in high-drinking rodent models","volume":"8","author":"Anderson","year":"2014","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.brainres.2018.08.025_b0025","doi-asserted-by":"crossref","first-page":"3438","DOI":"10.2174\/1568026616666150929111607","article-title":"Orexin receptor antagonists: historical perspectives and future opportunities","volume":"16","author":"Andrews","year":"2016","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.brainres.2018.08.025_b0030","unstructured":"Aranyi, P., Balogh, M., Batori, S., Bence, J., Finet, M., Kaui, Z., et al., 2005. Pyrimidine Derivatives as orexin receptors antagonists. WO 2005\/075458."},{"issue":"Suppl. 1","key":"10.1016\/j.brainres.2018.08.025_b0035","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.neuropharm.2008.06.060","article-title":"Role of lateral hypothalamic orexin neurons in reward processing and addiction","volume":"56","author":"Aston-Jones","year":"2009","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.brainres.2018.08.025_b0040","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.brainres.2009.09.106","article-title":"Lateral hypothalamic orexin\/hypocretin neurons: a role in reward-seeking and addiction","volume":"1314","author":"Aston-Jones","year":"2010","journal-title":"Brain Res."},{"key":"10.1016\/j.brainres.2018.08.025_b0045","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/bph.12639","article-title":"Orexin\/hypocretin role in reward: implications for opioid and other addictions","volume":"172","author":"Baimel","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.brainres.2018.08.025_b0050","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.neuropharm.2014.09.012","article-title":"Both Ox1r and Ox2r orexin receptors contribute to the cardiovascular and locomotor components of the novelty stress response in the rat","volume":"89","author":"Beig","year":"2015","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.brainres.2018.08.025_b0055","unstructured":"Bolli, M., Boss, C., Brotschi, C., Heidmann, B., Sifferlen, T., Williams, J., 2012. 2-(1,2,3-triazol-2-YL)benzamide and 3-(1,2,3-triazol-2-YL)picolinamide derivatives as orexin receptor antagonists. WO 2013\/068935."},{"key":"10.1016\/j.brainres.2018.08.025_b0060","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3389\/fphar.2017.00357","article-title":"Evaluation of JNJ-54717793 a novel brain penetrant selective orexin 1 receptor antagonist in two rat models of panic attack provocation","volume":"8","author":"Bonaventure","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.brainres.2018.08.025_b0065","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1124\/jpet.115.225466","article-title":"Characterization of JNJ-42847922, a selective orexin-2 receptor antagonist, as a clinical candidate for the treatment of insomnia","volume":"354","author":"Bonaventure","year":"2015","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.brainres.2018.08.025_b0070","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1124\/jpet.114.220392","article-title":"A selective orexin-1 receptor antagonist attenuates stress-induced hyperarousal without hypnotic effects","volume":"352","author":"Bonaventure","year":"2015","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.brainres.2018.08.025_b0075","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1021\/jm801296d","article-title":"Biomedical application of orexin\/hypocretin receptor ligands in neuroscience","volume":"52","author":"Boss","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.brainres.2018.08.025_b0080","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1016\/j.bmcl.2015.05.012","article-title":"Recent trends in orexin research\u20132010 to 2015","volume":"25","author":"Boss","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.brainres.2018.08.025_b0085","doi-asserted-by":"crossref","first-page":"19168","DOI":"10.1073\/pnas.0507480102","article-title":"Role for hypocretin in mediating stress-induced reinstatement of cocaine-seeking behavior","volume":"102","author":"Boutrel","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.brainres.2018.08.025_b0090","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/nm1544","article-title":"Promotion of sleep by targeting the orexin system in rats, dogs and humans","volume":"13","author":"Brisbare-Roch","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.brainres.2018.08.025_b0095","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1017\/S1461145713000333","article-title":"Central orexin (hypocretin) 2 receptor antagonism reduces ethanol self-administration, but not cue-conditioned ethanol-seeking, in ethanol-preferring rats","volume":"16","author":"Brown","year":"2013","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.brainres.2018.08.025_b0100","unstructured":"Coate, H.R., Dvorak, C.A., Preville, C., Shireman, B.T., 2014. Substituted piperidine compounds and their use as orexin receptor modulators. WO 2014\/165065."},{"key":"10.1016\/j.brainres.2018.08.025_b0105","doi-asserted-by":"crossref","first-page":"4201","DOI":"10.1016\/j.bmcl.2010.05.047","article-title":"Discovery of 3,9-diazabicyclo[4.2.1]nonanes as potent dual orexin receptor antagonists with sleep-promoting activity in the rat","volume":"20","author":"Coleman","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.brainres.2018.08.025_b0110","unstructured":"Congreve, M.S., Christopher, J.A., Tehan, B.G., Klair, S.S., Aves, S.J., 2014. OREXIN RECEPTOR ANTAGONISTS. WO\/2014\/006402."},{"key":"10.1016\/j.brainres.2018.08.025_b0115","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1073\/pnas.95.1.322","article-title":"The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity","volume":"95","author":"de Lecea","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.brainres.2018.08.025_b0120","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1124\/jpet.109.152009","article-title":"Blockade of orexin-1 receptors attenuates orexin-2 receptor antagonism-induced sleep promotion in the rat","volume":"330","author":"Dugovic","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.brainres.2018.08.025_b0125","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3389\/fnins.2014.00028","article-title":"Orexin-1 receptor blockade dysregulates REM sleep in the presence of orexin-2 receptor antagonism","volume":"8","author":"Dugovic","year":"2014","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.brainres.2018.08.025_b0130","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3389\/fnins.2014.00008","article-title":"Effects of a newly developed potent orexin-2 receptor-selective antagonist, compound 1 m, on sleep\/wakefulness states in mice","volume":"8","author":"Etori","year":"2014","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.brainres.2018.08.025_b0135","unstructured":"Fieldhouse, C., Glen, A., Maine, S., Fujimoto, T., Borbinson, J.S., 2015. 1,2-Substituted cyclopentanes as orexin receptor antagonists. WO 2015\/124932."},{"key":"10.1016\/j.brainres.2018.08.025_b0140","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3389\/fnins.2014.00005","article-title":"LSN2424100: a novel, potent orexin-2 receptor antagonist with selectivity over orexin-1 receptors and activity in an animal model predictive of antidepressant-like efficacy","volume":"8","author":"Fitch","year":"2014","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.brainres.2018.08.025_b0145","doi-asserted-by":"crossref","first-page":"5203","DOI":"10.1016\/j.bmc.2017.07.051","article-title":"Identification of highly selective and potent orexin receptor 1 antagonists derived from a dual orexin receptor 1\/2 antagonist based on the structural framework of pyrazoylethylbenzamide","volume":"25","author":"Futamura","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.brainres.2018.08.025_b0150","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1002\/cmdc.201000132","article-title":"Orexin receptor antagonists: a new concept in CNS disorders?","volume":"5","author":"Gatfield","year":"2010","journal-title":"ChemMedChem"},{"key":"10.1016\/j.brainres.2018.08.025_b0155","unstructured":"Gelin, C.F., Lebold, T.P., Shireman, B.T., Ziff, J.M., 2014. Substituted 2-azabicycles and their use as orexin receptor modulators. WO\/2014\/165070."},{"key":"10.1016\/j.brainres.2018.08.025_b0160","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/adb.12507","article-title":"Suvorexant, an orexin\/hypocretin receptor antagonist, attenuates motivational and hedonic properties of cocaine","volume":"23","author":"Gentile","year":"2018","journal-title":"Addict Biol."},{"key":"10.1016\/j.brainres.2018.08.025_b0165","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/npp.2017.158","article-title":"Effects of suvorexant, a dual orexin\/hypocretin receptor antagonist, on impulsive behavior associated with cocaine","volume":"43","author":"Gentile","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.brainres.2018.08.025_b0170","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1124\/pr.111.005546","article-title":"International Union of Basic and Clinical Pharmacology. LXXXVI. Orexin receptor function, nomenclature and pharmacology","volume":"64","author":"Gotter","year":"2012","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.brainres.2018.08.025_b0175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0016406","article-title":"Functional magnetic resonance imaging reveals different neural substrates for the effects of orexin-1 and orexin-2 receptor antagonists","volume":"6","author":"Gozzi","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.brainres.2018.08.025_b0180","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nature04071","article-title":"A role for lateral hypothalamic orexin neurons in reward seeking","volume":"437","author":"Harris","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.brainres.2018.08.025_b0185","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0167-0115(00)00199-3","article-title":"A selective orexin-1 receptor antagonist reduces food consumption in male and female rats","volume":"96","author":"Haynes","year":"2000","journal-title":"Regul. Pept."},{"key":"10.1016\/j.brainres.2018.08.025_b0190","doi-asserted-by":"crossref","first-page":"3178","DOI":"10.1021\/bi300136h","article-title":"Study of human Orexin-1 and -2 G-protein-coupled receptors with novel and published antagonists by modeling, molecular dynamics simulations, and site-directed mutagenesis","volume":"51","author":"Heifetz","year":"2012","journal-title":"Biochemistry (Mosc)"},{"key":"10.1016\/j.brainres.2018.08.025_b0195","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0014-5793(02)03101-0","article-title":"Orexin signaling in recombinant neuron-like cells","volume":"526","author":"Holmqvist","year":"2002","journal-title":"FEBS Lett."},{"key":"10.1016\/j.brainres.2018.08.025_b0200","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.1016\/j.bmcl.2012.04.122","article-title":"Disubstituted piperidines as potent orexin (hypocretin) receptor antagonists","volume":"22","author":"Jiang","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.brainres.2018.08.025_b0205","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/da.22403","article-title":"Orexin 1 and 2 receptor involvement in Co2 -induced panic-associated behavior and autonomic responses","volume":"32","author":"Johnson","year":"2015","journal-title":"Depress Anxiety"},{"key":"10.1016\/j.brainres.2018.08.025_b0210","unstructured":"Kamenecka, T., Jiang, R., Song, X., 2013. Substituted prolines\/piperidines as orexin receptor antagonists. WO2013\/119639."},{"key":"10.1016\/j.brainres.2018.08.025_b0215","unstructured":"Kamenecka, T.M., He, Y., Jiang, R., Nguyen, W., Song, X, 2014a. Substituted prolines\/piperidines as orexin receptor antagonists. US2014\/0364433."},{"key":"10.1016\/j.brainres.2018.08.025_b0220","unstructured":"Kamenecka, T.M., He, Y., Nguyen, W., Jiang, R., Song, X., 2014b. Substituted prolines\/piperidines as orexin receptor antagonists. US2014\/0364432."},{"key":"10.1016\/j.brainres.2018.08.025_b0225","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.pbb.2010.08.015","article-title":"Tobacco dependence, the insular cortex and the hypocretin connection","volume":"97","author":"Kenny","year":"2011","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.brainres.2018.08.025_b0230","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s40263-014-0179-x","article-title":"Orexin\/hypocretin based pharmacotherapies for the treatment of addiction: DORA or SORA?","volume":"28","author":"Khoo","year":"2014","journal-title":"CNS Drugs"},{"key":"10.1016\/j.brainres.2018.08.025_b0235","doi-asserted-by":"crossref","first-page":"270","DOI":"10.2533\/000942903777679361","article-title":"Tetrahydroisoquinolines as orexin receptor antagonists: strategies for lead optimization by solution-phase chemistry","volume":"57","author":"Koberstein","year":"2003","journal-title":"Chimia"},{"key":"10.1016\/j.brainres.2018.08.025_b0240","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1039\/c003468a","article-title":"Chemistry and biology of orexin signaling","volume":"6","author":"Kodadek","year":"2010","journal-title":"Mol. BioSyst."},{"key":"10.1016\/j.brainres.2018.08.025_b0245","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/sj.bjp.0705610","article-title":"Characterisation of the binding of [3H]-SB-674042, a novel nonpeptide antagonist, to the human orexin-1 receptor","volume":"141","author":"Langmead","year":"2004","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.brainres.2018.08.025_b0250","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.brainres.2009.07.072","article-title":"Regulation of alcohol-seeking by orexin (hypocretin) neurons","volume":"1314","author":"Lawrence","year":"2010","journal-title":"Brain Res."},{"key":"10.1016\/j.brainres.2018.08.025_b0255","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1038\/sj.bjp.0706789","article-title":"The orexin system regulates alcohol-seeking in rats","volume":"148","author":"Lawrence","year":"2006","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.brainres.2018.08.025_b0260","doi-asserted-by":"crossref","first-page":"4761","DOI":"10.1016\/j.bmcl.2013.06.057","article-title":"Selective orexin receptor antagonists","volume":"23","author":"Lebold","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.brainres.2018.08.025_b0265","doi-asserted-by":"crossref","DOI":"10.1007\/s00213-017-4673-y","article-title":"Hypocretin receptor 1 blockade produces bimodal modulation of cocaine-associated mesolimbic dopamine signaling","author":"Levy","year":"2017","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.brainres.2018.08.025_b0270","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.brainres.2016.01.049","article-title":"The highly selective orexin\/hypocretin 1 receptor antagonist GSK1059865 potently reduces ethanol drinking in ethanol dependent mice","volume":"1636","author":"Lopez","year":"2016","journal-title":"Brain Res."},{"key":"10.1016\/j.brainres.2018.08.025_b0275","doi-asserted-by":"crossref","first-page":"4568","DOI":"10.1523\/JNEUROSCI.22-11-04568.2002","article-title":"Selective activation of the extended ventrolateral preoptic nucleus during rapid eye movement sleep","volume":"22","author":"Lu","year":"2002","journal-title":"J. Neurosci."},{"key":"10.1016\/j.brainres.2018.08.025_b0280","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/B978-0-444-59489-1.00007-0","article-title":"Multiple roles for orexin\/hypocretin in addiction","volume":"198","author":"Mahler","year":"2012","journal-title":"Prog. Brain Res."},{"key":"10.1016\/j.brainres.2018.08.025_b0285","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1124\/mol.109.055152","article-title":"Biochemical and electrophysiological characterization of almorexant, a dual orexin 1 receptor (OX1)\/orexin 2 receptor (OX2) antagonist: comparison with selective OX1 and OX2 antagonists","volume":"76","author":"Malherbe","year":"2009","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.brainres.2018.08.025_b0290","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1124\/mol.110.064584","volume":"78","author":"Malherbe","year":"2010","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.brainres.2018.08.025_b0295","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/cne.1190","article-title":"Differential expression of orexin receptors 1 and 2 in the rat brain","volume":"435","author":"Marcus","year":"2001","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.brainres.2018.08.025_b0300","doi-asserted-by":"crossref","first-page":"6661","DOI":"10.1016\/j.bmcl.2012.08.109","article-title":"Hydrolytic instability of the important orexin 1 receptor antagonist SB-334867: possible confounding effects on in vivo and in vitro studies","volume":"22","author":"McElhinny","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.brainres.2018.08.025_b0305","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3389\/fnins.2014.00026","article-title":"Orexin 1 receptor antagonists in compulsive behavior and anxiety: possible therapeutic use","volume":"8","author":"Merlo Pich","year":"2014","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.brainres.2018.08.025_b0310","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0039131","article-title":"Dual hypocretin receptor antagonism is more effective for sleep promotion than antagonism of either receptor alone","volume":"7","author":"Morairty","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.brainres.2018.08.025_b0315","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1021\/acs.jmedchem.6b01418","article-title":"Design and synthesis of potent and highly selective orexin 1 receptor antagonists with a morphinan skeleton and their pharmacologies","volume":"60","author":"Nagase","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.brainres.2018.08.025_b0320","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0006-8993(99)01336-0","article-title":"Distribution of orexin neurons in the adult rat brain","volume":"827","author":"Nambu","year":"1999","journal-title":"Brain Res."},{"key":"10.1016\/j.brainres.2018.08.025_b0325","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.bmcl.2017.12.069","article-title":"Essential structure of orexin 1 receptor antagonist YNT-707, Part II: Drastic effect of the 14-hydroxy group on the orexin 1 receptor antagonistic activity","volume":"28","author":"Ohrui","year":"2018","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.brainres.2018.08.025_b0330","doi-asserted-by":"crossref","first-page":"5709","DOI":"10.1016\/j.bmc.2015.07.013","article-title":"The importance of the 6- and 7-positions of tetrahydroisoquinolines as selective antagonists for the orexin 1 receptor","volume":"23","author":"Perrey","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.brainres.2018.08.025_b0335","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1021\/acschemneuro.7b00402","article-title":"Synthesis and evaluation of orexin-1 receptor antagonists with improved solubility and CNS permeability","volume":"9","author":"Perrey","year":"2018","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.brainres.2018.08.025_b0340","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1021\/cn500330v","article-title":"Effect of 1-substitution on tetrahydroisoquinolines as selective antagonists for the orexin-1 receptor","volume":"6","author":"Perrey","year":"2015","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.brainres.2018.08.025_b0345","doi-asserted-by":"crossref","first-page":"6901","DOI":"10.1021\/jm400720h","article-title":"Substituted tetrahydroisoquinolines as selective antagonists for the orexin 1 receptor","volume":"56","author":"Perrey","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.brainres.2018.08.025_b0350","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1016\/j.bmcl.2011.03.048","article-title":"Diaryl urea analogues of SB-334867 as orexin-1 receptor antagonists","volume":"21","author":"Perrey","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.brainres.2018.08.025_b0355","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1021\/ml4004759","article-title":"Toward the development of bivalent ligand probes of cannabinoid CB1 and orexin OX1 receptor heterodimers","volume":"5","author":"Perrey","year":"2014","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.brainres.2018.08.025_b0360","doi-asserted-by":"crossref","first-page":"9996","DOI":"10.1523\/JNEUROSCI.18-23-09996.1998","article-title":"Neurons containing hypocretin (orexin) project to multiple neuronal systems","volume":"18","author":"Peyron","year":"1998","journal-title":"J. Neurosci."},{"key":"10.1016\/j.brainres.2018.08.025_b0365","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0960-894X(01)00343-2","article-title":"1,3-Biarylureas as selective non-peptide antagonists of the orexin-1 receptor","volume":"11","author":"Porter","year":"2001","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.brainres.2018.08.025_b0370","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1021\/cn500246j","article-title":"Hypocretin\/Orexin regulation of dopamine signaling and cocaine self-administration is mediated predominantly by hypocretin receptor 1","volume":"6","author":"Prince","year":"2015","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.brainres.2018.08.025_b0375","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.bmcl.2014.12.056","article-title":"Discovery of piperidine ethers as selective orexin receptor antagonists (SORAs) inspired by filorexant","volume":"25","author":"Raheem","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.brainres.2018.08.025_b0380","doi-asserted-by":"crossref","first-page":"977","DOI":"10.2174\/156802608784936746","article-title":"Orexin receptor antagonists: medicinal chemistry and therapeutic potential","volume":"8","author":"Roecker","year":"2008","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.brainres.2018.08.025_b0385","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/nrn2092","article-title":"The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness","volume":"8","author":"Sakurai","year":"2007","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.brainres.2018.08.025_b0390","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0092-8674(00)80949-6","article-title":"Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior","volume":"92","author":"Sakurai","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.brainres.2018.08.025_b0395","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1146\/annurev-pharmtox-010510-100528","article-title":"Orexin receptors: pharmacology and therapeutic opportunities","volume":"51","author":"Scammell","year":"2011","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.brainres.2018.08.025_b0400","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s00213-010-2127-x","article-title":"Selective blockade of the orexin-2 receptor attenuates ethanol self-administration, place preference, and reinstatement","volume":"215","author":"Shoblock","year":"2011","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.brainres.2018.08.025_b0405","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/sj.bjp.0703953","article-title":"SB-334867-A: the first selective orexin-1 receptor antagonist","volume":"132","author":"Smart","year":"2001","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.brainres.2018.08.025_b0410","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/j.1460-9568.2009.06844.x","article-title":"Orexin\/hypocretin signaling at the orexin 1 receptor regulates cue-elicited cocaine-seeking","volume":"30","author":"Smith","year":"2009","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.brainres.2018.08.025_b0415","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1016\/j.bmcl.2013.02.093","article-title":"Discovery, synthesis, selectivity modulation and DMPK characterization of 5-azaspiro[2.4]heptanes as potent orexin receptor antagonists","volume":"23","author":"Stasi","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.brainres.2018.08.025_b0420","unstructured":"Stasi, P.L., Rovati, L., 2011. Spiro amino compounds suitable for the treatment of inter alia sleep disorders and drug addiction. WO2011006960Rottapharm S.P.A."},{"key":"10.1016\/j.brainres.2018.08.025_b0425","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1002\/cmdc.201300003","article-title":"Discovery and characterization of ACT-335827, an orally available, brain penetrant orexin receptor type 1 selective antagonist","volume":"8","author":"Steiner","year":"2013","journal-title":"ChemMedChem"},{"key":"10.1016\/j.brainres.2018.08.025_b0430","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1017\/S1461145712000193","article-title":"The dual orexin receptor antagonist almorexant, alone and in combination with morphine, cocaine and amphetamine, on conditioned place preference and locomotor sensitization in the rat","volume":"16","author":"Steiner","year":"2013","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.brainres.2018.08.025_b0435","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.psyneuen.2012.07.016","article-title":"Examining the role of endogenous orexins in hypothalamus-pituitary-adrenal axis endocrine function using transient dual orexin receptor antagonism in the rat","volume":"38","author":"Steiner","year":"2013","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.brainres.2018.08.025_b0440","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1016\/j.bmc.2015.01.044","article-title":"Discovery and in vitro and in vivo profiles of N-ethyl-N-[2-[3-(5-fluoro-2-pyridinyl)-1H-pyrazol-1-yl]ethyl]-2-(2H\u20131,2,3-triazol -2-yl)-benzamide as a novel class of dual orexin receptor antagonist","volume":"23","author":"Suzuki","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.brainres.2018.08.025_b0445","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1124\/pr.109.001321","article-title":"Orexin\/hypocretin: a neuropeptide at the interface of sleep, energy homeostasis, and reward system","volume":"61","author":"Tsujino","year":"2009","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.brainres.2018.08.025_b0450","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/7854_2016_55","article-title":"The role of orexins\/hypocretins in alcohol use and abuse","volume":"33","author":"Walker","year":"2017","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"10.1016\/j.brainres.2018.08.025_b0455","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1124\/pr.112.005660","article-title":"Strategies to address low drug solubility in discovery and development","volume":"65","author":"Williams","year":"2013","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.brainres.2018.08.025_b0460","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S0896-6273(03)00330-1","article-title":"Distinct narcolepsy syndromes in Orexin receptor-2 and Orexin null mice: molecular genetic dissection of Non-REM and REM sleep regulatory processes","volume":"38","author":"Willie","year":"2003","journal-title":"Neuron"},{"key":"10.1016\/j.brainres.2018.08.025_b0465","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/bph.12261","article-title":"Discovery and development of orexin receptor antagonists as therapeutics for insomnia","volume":"171","author":"Winrow","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.brainres.2018.08.025_b0470","doi-asserted-by":"crossref","first-page":"4176","DOI":"10.1016\/j.bmcl.2017.07.011","article-title":"Essential structure of orexin 1 receptor antagonist YNT-707, Part I: Role of the 4,5-epoxy ring for binding with orexin 1 receptor","volume":"27","author":"Yamamoto","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.brainres.2018.08.025_b0475","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/nsmb.3183","article-title":"Structure and ligand-binding mechanism of the human OX1 and OX2 orexin receptors","volume":"23","author":"Yin","year":"2016","journal-title":"Nat. Struct. Mol. Biol."}],"container-title":["Brain Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006899318304475?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006899318304475?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T18:08:55Z","timestamp":1757786935000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006899318304475"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":95,"alternative-id":["S0006899318304475"],"URL":"https:\/\/doi.org\/10.1016\/j.brainres.2018.08.025","relation":{},"ISSN":["0006-8993"],"issn-type":[{"value":"0006-8993","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutics development for addiction: Orexin-1 receptor antagonists","name":"articletitle","label":"Article Title"},{"value":"Brain Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.brainres.2018.08.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"145922"}}